| Literature DB >> 19087328 |
Gang Yue1, Guanfang Shi, Marco A Azaro, Qifeng Yang, Guohong Hu, Minjie Luo, Kingsley Yin, Robert G Nagele, Daniel H Fine, Jin-Ming Yang, Honghua Li.
Abstract
BACKGROUND: Lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria with proved role in pathogenesis of sepsis. Brain injury was observed with both patients dead from sepsis and animal septic models. However, in vitro administration of LPS has not shown obvious cell damage to astrocytes and other relative cell lines while it does cause endothelial cell death in vitro. These observations make it difficult to understand the role of LPS in brain parenchymal injury.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19087328 PMCID: PMC2631585 DOI: 10.1186/1471-2164-9-608
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Illustration of results from the study of astrocyte death caused by LPS treatment followed by H. (A). Effect of LPS and H2O2 concentration on cell viability. "*" indicates statistically significantly different (α < 0.05) from PBS treatment in the same subgroups (the same H2O2 concentration), and "#" indicates statistically significantly different (α < 0.05) from sample pretreated with 1 μg/ml LPS in the same subgroup. Vertical bars represent range of variation of the cell viability error bars indexing the standard deviations (SD) based on three independent experiments. (B). The same set of data in (A) but are presented in percentages of viable cells compared with the PBS controls in the same subgroups.
Figure 2Illustration of microarray results. In each array, all the 1,135 oligonucleotide probes were spotted twice. (A). Microarray images for PBS control, 1 and 5 μg/ml LPS treatments; (B) Pie chart presentation of the expression profile of the1135 genes. (C) Illustration of the portion of significantly down- and up-regulated genes in the presence of 1 and 5 μg/ml LPS.
Correlation between gene expression and cell viability
| | cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11) | 5 | 0.7715 | 0.9635 | ||
| | glutathione S-transferase A4 (GSTA4) | 1 | 0.6140 | 0.8818 | 0.9360 | 0.9669 |
| | macrophage-stimulating protein (MST1) | 1 | 0.6693 | 0.9135 | 0.9589 | 0.9827 |
| | protein kinase C, epsilon (PRKCE) | 5 | 0.6189 | 0.8847 | 0.9382 | 0.9684 |
| | vasoactive intestinal peptide receptor 1 (VIPR1) | 5 | 0.7329 | 0.9462 | 0.9804 | |
| | cytochrome b-561 (CYB561) | 5 | 0.7711 | 0.9633 | ||
| | B-cell CLL/lymphoma 7A (BCL7A) | 1 | 0.8045 | 0.9765 | ||
| | sapiens complement component 5 (C5) | 1 | 0.5590 | 0.8478 | 0.9100 | 0.9473 |
| | interleukin 6 receptor (IL6R) | 1 | 0.6850 | 0.9220 | 0.9648 | |
| | notch homolog 3 (Drosophila) (NOTCH3), | 1 | 0.7489 | 0.9536 | 0.9848 | |
| | poly (ADP-ribose) polymerase family, member 1 (PARP1), | 1 | 0.6838 | 0.9214 | 0.9643 | 0.9862 |
| | reticulon 1 (RTN1) | 1 | 0.6122 | 0.8807 | 0.9352 | 0.9663 |
| | apolipoprotein E (APOE) | 5 | 0.7164 | 0.9381 | 0.9754 | 0.9927 |
| | early growth response 1 (EGR1) | 5 | 0.7975 | 0.9739 | ||
| | aspartylglucosaminidase (AGA) | 1 | 0.5997 | 0.8732 | 0.9295 | 0.9621 |
| | solute carrier family 26, member 4 (SLC26A4) | 5 | 0.7566 | 0.9571 | 0.9868 | 0.9981 |
| | RAB3D, member RAS oncogene family (RAB3D) | 5 | 0.8235 | 0.9830 | ||
| | solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 (SLC7A1) | 5 | 0.6901 | 0.9247 | 0.9666 | 0.9876 |
| | folate receptor 1 (adult) (FOLR1) | 1 | 0.6441 | 0.8994 | 0.9489 | 0.9760 |
| | synovial sarcoma, X breakpoint 1 (SSX1) | 1 | 0.7612 | 0.9591 | 0.9879 | |
| | SIX homeobox 1 (SIX1) | 5 | 0.6397 | 0.8969 | 0.9471 | 0.9748 |
| | T-box 2 (TBX2) | 5 | 0.6035 | 0.8755 | 0.9312 | 0.9634 |
| | aryl hydrocarbon receptor (AHR) | 1 | 0.6673 | 0.9124 | 0.9582 | 0.9822 |
| | non-metastatic cells 1, protein (NM23A) expressed in (NME1) | 1 | 0.5921 | 0.8685 | 0.9260 | 0.9595 |
| | tropomyosin 2 (beta) (TPM2) | 1 | 0.7030 | 0.9314 | 0.9710 | |
| | villin-like (VILL) | 1 | 0.5310 | 0.8296 | 0.8956 | 0.9361 |
| | SH3-domain binding protein 2 (SH3BP2) | 5 | 0.7448 | 0.9517 | 0.9837 | |
| | ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) (ADAMTS5) | 1 | 0.6070 | 0.8776 | 0.9328 | 0.9646 |
| | elaC homolog 2 (E. coli) (ELAC2) | 1 | 0.6819 | 0.9203 | 0.9636 | 0.9858 |
| | frizzled homolog 6 (Drosophila) (FZD6), | 1 | 0.7105 | 0.9352 | 0.9735 | |
| | solute carrier family 29 (nucleoside transporters), member 3 (SLC29A3) | 1 | 0.6177 | 0.8840 | 0.9376 | 0.9680 |
| | nuclear receptor subfamily 1, group D, member 1 (NR1D1) | 1 | 0.6802 | 0.9194 | 0.9630 | 0.9854 |
| | ribosomal protein S8 (RPS8) | 1 | 0.6111 | 0.8801 | 0.9347 | 0.9659 |
| | synuclein, gamma (breast cancer-specific protein 1) (SNCG) | 1 | 0.7776 | 0.9660 | 0.9916 | |
| | tripartite motif-containing 33 (TRIM33), | 1 | 0.7008 | 0.9303 | 0.9703 | |
| | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) | 1 | 0.6613 | 0.9091 | 0.9558 | 0.9807 |
| Y12863 | growth factor FIGF | 5 | 0.7831 | 0.9683 | ||
| | growth factor receptor-bound protein 2 (GRB2) | 1 | 0.6311 | 0.8919 | 0.9434 | 0.9722 |
| M35410 | insulin-like growth factor binding protein 2 (IGFBP2) | 1 | 0.6801 | 0.9194 | 0.9630 | 0.9854 |
| | somatostatin receptor 2 (SSTR2) | 1 | 0.9252 | 0.9871 | 0.9658 | |
| | ets variant gene 7 (TEL2 oncogene) (ETV7) | 5 | 0.6810 | 0.9198 | 0.9633 | 0.9856 |
| | FBJ murine osteosarcoma viral oncogene homolog B (FOSB) | 5 | 0.6889 | 0.9240 | 0.9662 | 0.9873 |
| | fibroblast growth factor receptor 4 (FGFR4) | 5 | 0.6720 | 0.9150 | 0.9600 | 0.9834 |
| | retinoid × receptor, alpha (RXRA) | 5 | 0.9264 | 0.9866 | 0.9650 | |
| | splicing factor 1 (SF1) | 5 | 0.8712 | |||
| | v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) | 5 | 0.8257 | 0.9837 | ||
| | peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 (SERPINA5) | 1 | 0.6092 | 0.8790 | 0.9339 | 0.9653 |
| | cyclooxygenase-2 (COX2) | 1 | 0.5186 | 0.8213 | 0.8890 | 0.9308 |
| | RAB6B, member RAS oncogene family (RAB6B) | 1 | 0.7002 | 0.9299 | 0.9701 | |
| | glycoprotein A33 (transmembrane) (GPA33) | 1 | -0.9658 | -0.9878 | -0.9589 | -0.9251 |
| | desmoglein 2 (DSG2) | 1 | -0.6663 | -0.9119 | -0.9578 | -0.9820 |
| | 3-phosphoinositide dependent protein kinase-1 (PDPK1) | 1 | -0.5869 | -0.8653 | -0.9235 | -0.9577 |
| | neurotrophic tyrosine kinase receptor, type 2 (NTRK2) | 1 | -0.6822 | -0.9205 | -0.9637 | -0.9858 |
| | nasopharyngeal carcinoma susceptibility protein; lz16/ankyrin repeat domain 11 (ANKRD11) | 1 | -0.7789 | -0.9666 | ||
*Genes with a Pearson's product-moment correlation coefficient (r2) > 0.85 are listed. Those with coefficient r > 0.988 (α < 0.05) are in bold face.
Genes associated with cytokines, cell death, and growth
| | interleukin beta; il1 b | U/A |
| | interleukin 6 (interferon; beta 2); IL-6 | U/A |
| | interleukin 12a; il12a | U/A |
| | interleukin 11; il11 | Up |
| | interleukin 13 receptor alpha 2; il13ra2 | Up |
| | interleukin 6 receptor; IL-6Ra | Down |
| | interleukin 2; il2 | U/D |
| | interleukin 3 colony-stimulating factor multiple; il3 | U/D |
| | interleukin 4; il4 | U/D |
| | interleukin 5 colony-stimulating factor eosinophil; il5 | U/D |
| | interleukin 9; il9 | U/D |
| | interleukin 13; il13 | U/D |
| | interleukin 18; il18 | U/D |
| | tumor necrosis factor ligand superfamily member 14; tnfsf14 | Up |
| | tumor necrosis factor receptor 55kd; tnfrsf1a | U/A |
| | tumor necrosis factor receptor 2 75kd; tnfrsf1b | U/A |
| | tumor necrosis factor alpha-induced protein 2; tnfaip2 | U/A |
| | tumor necrosis factor receptor superfamily member 6b precursor isoform d; tnfrsf6b | U/A |
| | tumor necrosis factor ligand superfamily member 9; tnfsf9 | U/A |
| | tumor necrosis factor ligand superfamily member 10; tnfsf10 | U/A |
| | tumor necrosis factor receptor superfamily member 10b; tnfrsf10b | U/A |
| | tumor necrosis factor ligand superfamily member 13b; tnfsf13b | U/A |
| | tumor necrosis factor receptor superfamily member 14; herpesvirus entry mediator; tnfrsf14 | U/A |
| | tumor necrosis factor cachectin (TNF) | U/D |
| | tumor necrosis factor ligand superfamily member 8; tnfsf8 | U/D |
| | tumor necrosis factor receptor superfamily member 10a; tnfrsf10a | U/D |
| | Bcl-2 binding component 3 (bbc3) | Up |
| | casp8 and fadd-like apoptosis regulator; cflar | U/A |
| | caspase 10 isoform d small subunit; casp10 | U/A |
| | caspase 8 isoform c; casp8 | U/A |
| | apoptosis apo-1 antigen 1; tnfrsf6 | U/A |
| | apoptotic protease activating factor isoform b; apaf1 | U/A |
| | BCL2-like 2; Bcl-w | U/A |
| | bcl2-antagonist of cell death protein; bad | U/A |
| | Bcl-2-associated athanogene; BAG-1 | U/A |
| | beclin coiled-coil myosin-like bcl2-interacting protein; becn1 | U/A |
| | apoptosis apo-1 antigen ligand 1; tnfsf6 | U/D |
| | apoptosis inhibitor; fksg2 | U/D |
| | bcl2-associated athanogene 4; bag4 | U/D |
| | nerve growth factor receptor; ngfr | U/A |
| | nerver growth factor; beta polypeptide; NGF | U/A |
*U/A, unaffected. U/D, undetectable